Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease
Phase I-II Study Using Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease
Sponsor: Medical College of Wisconsin
Terminated
The DSMB felt the risks of the study now outweighed the potential benefits.
Listed as NCT01475162, this PHASE1/PHASE2 trial focuses on Acute Graft Versus Host Disease and remains terminated or withdrawn. Sponsored by Medical College of Wisconsin, it has been updated 10 times since 2011, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
-
Feb 2020 — Mar 2020 [monthly]
Terminated PHASE1_PHASE2
▶ Show 5 earlier versions
-
Jun 2018 — Feb 2020 [monthly]
Terminated PHASE1_PHASE2
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
-
Mar 2018 — May 2018 [monthly]
Terminated PHASE1_PHASE2
-
Aug 2017 — Mar 2018 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2017 — Aug 2017 [monthly]
Terminated PHASE1_PHASE2
First recorded
Aug 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Medical College of Wisconsin
For direct contact, visit the study record on ClinicalTrials.gov .